At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 24 enrolled
Drug / intervention
Soticlestat +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 as an Adjunctive Therapy in Adult Subjects With Chronic Complex Regional Pain Syndrome
In Brief
A Phase 2 clinical trial evaluating Soticlestat and Placebo for Complex Regional Pain Syndrome. Completed, enrolled 24 participants across 3 sites.
Detailed Summary
The purpose of this study is to investigate the effect of soticlestat (TAK-935) on calculated 24-hour average pain intensity by the numeric pain scale (NPS).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsComplex Regional Pain Syndrome
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedJun 2019
Enrollment StartJul 2019
Primary CompletionJun 2020
Study CompletionOct 2020
TodayJul 2026
First PostedJun 19, 2019
Enrollment StartJul 23, 2019
Primary CompletionJun 29, 2020
Study CompletionOct 28, 2020
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 7.0 years ago
Interventions
Soticlestatdrug
Soticlestat tablets
Placebodrug
Soticlestat matching placebo tablets